109 Combined Modality Conference: " Resistance to Endocrine Therapy in ER+ Breast Cancer: Insights from Bedside to Bench Studies " (031121)-NO CME

Dallas, TX US
March 11, 2021

The combined modality therapy approach, including the medical, surgical and radiation arms of cancer therapy, provides
the best treatment options for the management of a wide variety of cancer patients with complex problems. This course is
designed to educate an audience specializing in the care of cancer patients. This conference provides a forum for
multimodality interaction that promotes discussion of the most recent clinical research affecting patient care, as well as
bringing oncology specialists together to review cases and make recommendations for managing cancer patients.

Target Audience

Medical Radiation, and Surgical Oncologists; Radiologists; Pathologists; Urologists; Neurologists; UTSW Faculty, Fellows
and Residents in training; and private practice oncologists

Learning Objectives

At the conclusion of this activity, participants should be able to:

  1. Review the management of a diversified group of cancer patients through case presentations with pathologic and radiologic review and discussions by medical, radiation and surgical oncologists
  2. Distinguish the importance of the interaction of surgical, medical and radiation modalities in the treatment of these patients
  3. Present the most recent advances in cancer therapy and basic cancer research from a clinical and laboratory perspective, with an emphasis on new translational research approaches.
Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
03/11/2021
Course expires: 
03/11/2021
Event starts: 
03/11/2021 - 7:30am CST
Event ends: 
03/11/2021 - 8:30am CST
Cost:
$0.00
UT Southwestern Medical Center
2201 Inwood Road
(NC) 8.212 Conference Room Seay
Dallas, TX 75235
United States
Speaker(s)

Carlos Arteaga, Professor & Director, Simmons Comprehensive Cancer Center, Internal Medicine, Office of the Dean - Southwestern Medical School

has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with AstraZeneca;.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.